Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

July 11, 2019July 11, 2019

Non-Invasive Prenatal Screening Test for Sickle Cell Appears Possible, Study Reports

News

A non-invasive prenatal test to diagnose a risk of sickle cell disease in a baby is possible and may be available in clinics in a near future, if further testing ... Read more

June 27, 2019June 27, 2019

Early Treatment with Hydroxyurea Lessened SCD Severity Among Infants, Study Shows

News

Treatment with hydroxyurea since early infancy, starting at the age of one, is effective and safe at preventing sickle cell disease (SCD) complications, a follow-up study has found. The ... Read more

June 25, 2019June 25, 2019

Investigational Oral Inhibitor IMR-687 Shows Promising Results in Ongoing Phase 2 Clinical Trial

News

Imara’s investigational oral inhibitor IMR-687 is well-tolerated, and shows signs of potential for lowering blood biomarkers of sickle cell anemia (SCA), early data from a Phase 2 trial show. ... Read more

May 23, 2019May 23, 2019

Participants Sought for Trial Evaluating Olinciguat for Sickle Cell Disease

News

The Phase 2 STRONG-SCD clinical trial evaluating olinciguat as an investigational therapy for sickle cell disease is seeking participants. Olinciguat, being developed by Cyclerion Therapeutics (a spin-off of Ironwood Pharmaceuticals), ... Read more

May 14, 2019May 14, 2019

Cognitive Function May Be Affected in Adults with Sickle Cell Disease, Study Suggests

News

Adults with sickle cell disease score worse than their healthy, unaffected siblings on cognitive tests, despite treatment with hydroxyurea, a study reports. The study “Neurocognitive functioning in symptomatic adults ... Read more

March 21, 2019March 21, 2019

More Curative Bone Marrow Transplants are Successful When Patients Given Double the Radiation Beforehand, Study Says

News

The success rate of bone marrow transplants for patients with sickle cell disease or beta thalassemia, from only “half-matched” donors, increased by doubling the radiation delivered to patients’ bodies ... Read more

February 28, 2019February 28, 2019

First Patient Enrolled in Phase 1/2 Trial Testing CTX001 for Severe Sickle Cell Disease

News

A Phase 1/2 clinical trial evaluating investigational therapy CTX001 for severe sickle cell disease (SCD) has enrolled its first patient in the U.S., and treatment is expected to begin by mid-2019. The ... Read more

January 22, 2019January 22, 2019

Safety and Early Hints of Benefit Seen in Phase 1b Trial of PF-04447943

News

Sickle cell disease (SCD) patients were safely treated with a phosphodiesterase 9A (PDE9) inhibitor therapy called PF-04447943 with no serious side effects reported and possible evidence of fewer vaso-occlusion ... Read more

January 7, 2019January 8, 2019

CTX001 Earns FDA’s Fast Track Status for Treating Sickle Cell Disease

News

The U.S. Food and Drug Administration (FDA) has awarded fast track status to investigational therapy CTX001 to treat sickle cell disease. A Phase 1/2 clinical trial (NCT03745287) is recruiting patients. CTX001 uses the CRISPR gene-editing technology ... Read more

April 19, 2018April 19, 2018

Sickle Cell Disease Researchers Identify a Children’s Stroke Prediction Tool

News

The amount of oxygen the blood loses when traveling through the brain could help identify children with sickle cell disease who are at risk of having a stroke, a ... Read more